Implantation of human olfactory ecto-mesenchymal stem cells restores locomotion in a rat model of Parkinson's disease.
Farhadi M, Boroujeni ME, Kamrava SK, Bagher Z, Tehrani AM, Aghajanpour F, Ezi S, Soltani R, Khatmi A, Alizadeh R
Transplanting human stem cells into the brains of rats with Parkinson's disease restores movement and increases markers associated with dopamine neuron function. This preclinical study demonstrates that these specific stem cells can improve motor symptoms in an animal model, but it does not provide evidence for treatment in humans or children with NR4A2-related syndromes.
- Human stem cells improved movement in rats with Parkinson's disease.
- The treatment increased dopamine-related markers in the brain tissue.
- This is an animal study, not a human clinical trial.
- No data exists for NR4A2 mutations or pediatric patients.
Quantitative Immunohistochemistry to Measure Regional Expression of Nurr1 in the Brain and the Effect of the Nurr1 Heterozygous Genotype.
Kummari E, Guo-Ross SX, Partington HS, Nutter JM, Eells JB
This study maps Nurr1 protein levels across different brain regions in mice and shows that having only one working copy of the gene reduces protein amounts by roughly a quarter to half. It also finds that brief seizures cause temporary spikes in Nurr1 levels in specific hippocampal areas before returning to normal. The research provides baseline data on how Nurr1 is distributed in the brain but does not test treatments or analyze human patients.
- Nurr1 protein levels vary significantly across different mouse brain regions.
- Heterozygous mice show a 21-49% reduction in Nurr1 protein compared to normal mice.
- Seizures cause temporary increases in Nurr1 in the dentate gyrus within hours.
- The study uses only mouse models and does not involve human participants.
- No therapeutic interventions or clinical outcomes are reported.
DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases.
Takeda Y, Demura M, Yoneda T, Takeda Y
This study examines how DNA methylation regulates blood pressure genes in cardiovascular disease, noting that methylation can block the binding of NR4A2 (NURR1) to DNA. The research focuses on heart and adrenal gland physiology rather than neurological development or motor symptoms associated with NR4A2 syndromes.
- NR4A2 binding to DNA diminishes when its recognition sites are methylated.
- The paper links gene methylation to cardiovascular diseases like hypertension.
- Findings focus on heart and adrenal tissue, not the brain or nervous system.
- No clinical data or treatment implications for NR4A2-related neurodevelopmental disorders.
Magnetic Targeting of Human Olfactory Mucosa Stem Cells Following Intranasal Administration: a Novel Approach to Parkinson's Disease Treatment.
Simorgh S, Bagher Z, Farhadi M, Kamrava SK, Boroujeni ME, Namjoo Z, Hour FQ, Moradi S, Alizadeh R
This study demonstrates that magnetically targeting stem cells delivered through the nose improves motor symptoms and increases dopaminergic markers in rats with Parkinson's disease. The approach enhances the therapeutic effect of olfactory stem cells by directing them to the injured brain area.
- Magnetic targeting directs stem cells to the brain via the nose in rat models.
- Treatment reduces motor dysfunction and boosts dopaminergic neuron markers.
- The study uses animal models, not human patients or NR4A2 genetics.
Dibutyl phthalate disrupts conserved circadian rhythm in Drosophila and human cells.
Liu W, Cao H, Liao S, Kudłak B, Williams MJ, Schiöth HB
Exposure to dibutyl phthalate (DBP), a common plasticizer, disrupts circadian rhythm regulation in both fruit flies and human cells. The study identifies that DBP alters the expression of NR4A2 (Hr38 in flies) and other core clock genes, leading to behavioral changes in flies and cellular proliferation issues in human breast cells.
- DBP exposure disrupts circadian rhythm gene expression in Drosophila and human cells.
- NR4A2 (Hr38) expression is altered by DBP, affecting downstream signaling pathways.
- DBP modifies adult fruit fly circadian behavior without impacting eye development.
- DBP promotes proliferation and migration in human breast cells at disruptive doses.
Correction to Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
Munoz-Tello P, Lin H, Khan P, de Vera IMS, Kamenecka TM, Kojetin DJ
This paper corrects previous findings regarding which NR4A ligands directly bind and modulate the Nurr1 receptor. It clarifies the molecular interactions of these compounds without introducing new clinical data or treatments.
- The study corrects prior errors in identifying NR4A ligands that bind Nurr1.
- It refines understanding of how specific molecules modulate the orphan nuclear receptor.
- The work focuses on molecular binding mechanics rather than therapeutic outcomes.
- No human trials or clinical applications are reported in this correction.
Caveolin-1 downregulation promotes the dopaminergic neuron-like differentiation of human adipose-derived mesenchymal stem cells.
Han C, Wang YJ, Wang YC, Guan X, Wang L, Shen LM, Zou W, Liu J
This study shows that reducing caveolin-1 levels helps human fat-derived stem cells turn into dopamine-producing neurons in a lab dish. The researchers used RNA interference to lower caveolin-1, which increased the expression of key dopaminergic markers like Nurr1 and tyrosine hydroxylase. This suggests caveolin-1 acts as a brake on this specific cell differentiation process.
- Caveolin-1 levels drop when stem cells become dopamine neurons.
- Silencing caveolin-1 boosts dopaminergic marker expression in fat stem cells.
- The study uses human adipose-derived mesenchymal stem cells.
- Findings are limited to in vitro cell culture models.
- No animal or human clinical data is presented.
NF‑κB is negatively associated with Nurr1 to reduce the inflammatory response in Parkinson's disease.
Gao H, Wang D, Jiang S, Mao J, Yang X
Blocking the inflammatory protein NF-κB in damaged nerve cells restores levels of Nurr1 and dopamine-producing markers, thereby reducing inflammation. This suggests that inhibiting NF-κB could protect dopaminergic neurons from inflammatory damage.
- Inhibiting NF-κB increases cell survival in inflamed nerve cells.
- NF-κB inhibition restores Nurr1 and dopamine marker levels.
- The study uses PC12 rat cells, not human patients.
- No clinical treatment or trial data is presented.
DNA methylation and exposure to violence among African American young adult males.
Saadatmand F, Gurdziel K, Jackson L, Kwabi-Addo B, Ruden DM
Exposure to violence alters DNA methylation patterns in genes related to the central nervous system and immune function. The study identifies specific epigenetic changes in NR4A2 and other stress-response genes associated with high levels of violence exposure.
- Violence exposure correlates with altered DNA methylation in CNS and immune-related genes.
- NR4A2 shows higher methylation levels in individuals with low violence exposure.
- Other identified genes include NR4A3, HDAC4, SHANK2, and NRG1.
- Findings suggest violence impacts epigenetic regulation of stress response pathways.
A single-cell survey of the human glomerulonephritis.
Chen Z, Zhang T, Mao K, Shao X, Xu Y, Zhu M, Zhou H, Wang Q, Li Z, Xie Y, Yuan X, Ying L, Zhang M, Hu J, Mou S
This study maps the cellular changes in various kidney diseases using single-cell sequencing and identifies NR4A2 as a gene highly expressed in membranous nephropathy. The research focuses entirely on kidney pathology and immune responses, with no connection to NR4A2-related neurological syndromes or dopaminergic function.
- NR4A2 appears as a marker for membranous nephropathy, not neurological disease.
- The study analyzes kidney tissue from patients with glomerulonephritis and related conditions.
- No findings relate to NR4A2 syndrome, Parkinson's, or dopaminergic neurons.
- This is basic molecular biology of kidney disease with no clinical relevance to the child.
microRNAs (miR 9, 124, 155 and 224) transdifferentiate mouse macrophages to neurons.
Challagundla N, Agrawal-Rajput R
This study demonstrates that specific microRNAs can reprogram mouse macrophages into functional neurons in a laboratory setting. The research provides proof-of-concept for direct cellular reprogramming but does not involve human patients or NR4A2-specific genetic mechanisms.
- Mouse macrophages convert to functional neurons using four specific microRNAs.
- The process avoids exogenous transcription factors and teratoma formation risks.
- Reprogrammed neurons show electrical activity and calcium responses.
- Bone marrow and blood cells also undergo this transdifferentiation.
- No human data or NR4A2 gene targeting is included.
Impaired neurite development and mitochondrial dysfunction associated with calcium accumulation in dopaminergic neurons differentiated from the dental pulp stem cells of a patient with metatropic dysplasia.
Sun X, Kato H, Sato H, Torio M, Han X, Zhang Y, Hirofuji Y, Kato TA, Sakai Y, Ohga S, Fukumoto S, Masuda K
A specific genetic mutation in the TRPV4 channel causes calcium buildup and mitochondrial failure in dopaminergic neurons, leading to impaired nerve growth. This study identifies mitochondrial dysfunction as a potential therapeutic target for neuropsychiatric symptoms associated with this unrelated skeletal disorder.
- TRPV4 gain-of-function mutations disrupt calcium balance in dopaminergic neurons.
- Mutant neurons show impaired neurite development and reduced energy production.
- Mitochondrial dysfunction drives the neurodevelopmental defects observed in this model.
- Targeting mitochondria may alleviate neuropsychiatric symptoms in TRPV4-related diseases.
Exosomal miR-409-3p secreted from activated mast cells promotes microglial migration, activation and neuroinflammation by targeting Nr4a2 to activate the NF-κB pathway.
Hu L, Si L, Dai X, Dong H, Ma Z, Sun Z, Li N, Sha H, Chen Y, Qian Y, Zhang Z
This study shows that activated mast cells release exosomes containing miR-409-3p, which enter microglial cells and trigger neuroinflammation by suppressing the NR4A2 protein. This mechanism highlights a specific molecular pathway where NR4A2 normally acts to restrain inflammatory responses in the brain.
- Mast cell exosomes deliver miR-409-3p to microglia, promoting their activation and migration.
- miR-409-3p targets and suppresses NR4A2, leading to increased NF-κB inflammatory signaling.
- NR4A2 functions as a brake on neuroinflammation in this specific mast cell-microglia interaction.
- The findings rely entirely on murine cell cultures and do not involve human patients.
Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.
Willems S, Ohrndorf J, Kilu W, Heering J, Merk D
Researchers identify small chemical fragments that activate the Nurr1 protein in human cells, providing new tools to study how this receptor works. These compounds enhance gene expression and promote protein interactions but remain early-stage research tools rather than treatments.
- Small chloroquinolineamine fragments activate Nurr1 transcriptional activity in human astrocytes.
- Compounds induce Nurr1 dimerization and recruit co-regulators to the ligand binding domain.
- Findings clarify Nurr1 activation mechanisms but do not test efficacy in animals or humans.
- These molecules serve as chemical biology tools for future drug discovery efforts.
Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson's Disease. A Systematic Review.
Kambey PA, Kanwore K, Ayanlaja AA, Nadeem I, Du Y, Buberwa W, Liu W, Gao D
This review hypothesizes that low levels of the NR4A2 protein cause GDNF therapy to fail in Parkinson's disease by preventing the production of new dopamine neurons. It suggests that restoring NR4A2 function could be a necessary step for such treatments to work.
- GDNF trials failed in humans despite success in animal models.
- NR4A2 is required for GDNF to stimulate dopamine neuron growth.
- Low NR4A2 levels may explain why GDNF therapy does not help patients.
The Pathology of Morphine-Inhibited Nerve Repair and Morphine-Induced Nerve Damage Is Mediated via Endoplasmic Reticulum Stress.
Liu J, Yi S, Shi W, Zhang G, Wang S, Qi Q, Cong B, Li Y
Acute and prolonged morphine exposure damages nerve cells in the rat brain's cortex, impairs the growth and development of new neurons, and activates a stress response in cellular structures called the endoplasmic reticulum. This stress response is linked to the reduced activity of NURR1, a protein important for brain cell health and function.
- Morphine harms brain nerve cells in rats
- New neuron growth is blocked by morphine
- Endoplasmic reticulum stress is triggered by morphine
- NURR1 levels drop with morphine use
- This stress may stop brain repair after injury
Novel peripheral role of Nurr-1/GDNF/AKT trajectory in carvedilol and/or morin hydrate hepatoprotective effect in a model of hepatic ischemia/reperfusion.
El Sayed NF, Abdallah DM, Awad AS, Ahmed KA, El-Abhar HS
Carvedilol and morin hydrate protect the liver from injury in a rat model by activating the Nurr-1/GDNF/AKT pathway, reducing inflammation and cell death, boosting antioxidant defenses, and enhancing cellular cleanup processes. The combination of both drugs works better than either alone.
- Nurr-1/GDNF/AKT pathway is key to liver protection
- Drugs reduce inflammation and cell death
- Combination therapy is more effective
- Enhances cellular cleanup and antioxidant defenses
- Improves liver function and structure
The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington's Disease Mice.
Hecklau K, Mueller S, Koch SP, Mehkary MH, Kilic B, Harms C, Boehm-Sturm P, Yildirim F
Inhibiting specific enzymes in the brains of Huntington's disease mice partially corrects gene expression errors, including those involving NR4A2, and modestly improves motor coordination. This preclinical study does not test treatments for NR4A2-related syndrome or demonstrate clinical benefits in humans.
- HDAC1/3 inhibition normalizes NR4A2 gene expression in Huntington's disease mouse models.
- Treatment yields only modest improvements in motor skill learning and coordination deficits.
- The therapy does not reverse brain atrophy or affect anxiety-like behaviors in mice.
- This is a preclinical study with no human clinical data or direct relevance to NR4A2 syndrome treatment.
PT3: A Novel Benzamide Class Histone Deacetylase 3 Inhibitor Improves Learning and Memory in Novel Object Recognition Mouse Model.
Pulya S, Mahale A, Bobde Y, Routholla G, Patel T, Swati, Biswas S, Sharma V, Kulkarni OP, Ghosh B
This preclinical study shows that a new drug called PT3 improves memory and increases the expression of NR4A2 in mice. The findings are limited to animal models and do not provide evidence for human treatment or safety.
- PT3 is an HDAC3 inhibitor that crosses the blood-brain barrier in mice.
- Treatment improved long-term memory in a mouse behavioral test.
- NR4A2 expression increased in mouse brain tissue after PT3 administration.
- The study focuses on age-related memory loss and Alzheimer's disease models.
- No human clinical data or NR4A2 syndrome-specific outcomes are reported.
Targeting NR4A Nuclear Receptors to Control Stromal Cell Inflammation, Metabolism, Angiogenesis, and Tumorigenesis.
Crean D, Murphy EP
This review explains how NR4A receptors regulate inflammation, metabolism, and tumor growth in stromal cells. It focuses on the role of these receptors in rheumatoid arthritis and cancer rather than neurological development or movement disorders.
- NR4A receptors act as sensors for cellular stress and inflammation in the body.
- The paper reviews NR4A1 and NR4A2 roles in stromal cell behavior and immune response.
- It discusses how these receptors influence tissue hyperplasia and angiogenesis in arthritis.
- The text covers NR4A involvement in tumor-stromal communication and cancer development.
- No clinical data or treatment strategies for NR4A2-related neurodevelopmental conditions are presented.
Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice.
Sheng Y, Ma R, Yu C, Wu Q, Zhang S, Paulsen K, Zhang J, Ni H, Huang Y, Zheng Y, Qian Z
This study found that reduced c-Myc levels impair blood stem cell function in mice by affecting genes like NR4A2, which are important for stem cell survival and dormancy. The results suggest that c-Myc influences blood cell development through interactions with NR4A2 and other genes, and may affect how stem cells respond to signals from their environment. However, the findings are specific to blood stem cells and mouse models, not directly about NR4A2-related syndrome in humans.
- c-Myc regulates NR4A2 and other genes critical for blood stem cell function
- NR4A2 helps maintain blood stem cell dormancy and survival
- Reduced c-Myc improves outcomes in mice with defective blood cell development
- Findings are in mouse blood stem cells, not human NR4A2 syndrome
- No direct therapeutic implications for NR4A2-related neurodevelopmental disorders
Role of the Orphan Nuclear Receptor NR4A Family in T-Cell Biology.
Odagiu L, May J, Boulet S, Baldwin TA, Labrecque N
This review explains how NR4A family proteins regulate T-cell development and immune responses. It does not provide information relevant to the neurodevelopmental or motor symptoms associated with NR4A2 syndrome.
- NR4A1, NR4A2, and NR4A3 act as transcription factors in T cells.
- These genes are induced during T-cell receptor triggering and antigen recognition.
- The paper reviews T-cell life cycles from thymic differentiation to peripheral responses.
- It covers immune responses against infections and cancer.
- No clinical data or neurodevelopmental insights for NR4A2 syndrome are included.
Attenuated macrophage activation mediated by microRNA-183 knockdown through targeting NR4A2.
Gong FH, Long L, Yang YS, Shen DH, Zhang YS, Wang XS, Zhang XP, Xiao XQ
This study shows that reducing a specific microRNA (miR-183) lowers inflammation in immune cells by increasing NR4A2 levels, suggesting a potential treatment for atherosclerosis. The research focuses on heart and blood vessel health rather than the neurological or developmental aspects of NR4A2-related syndromes.
- Reducing miR-183 increases NR4A2 expression in immune cells called macrophages.
- This change reduces inflammation and improves cholesterol handling in these cells.
- The findings suggest a potential therapy for atherosclerosis, not neurological conditions.
- NR4A2 acts as a downstream target of miR-183 in this inflammatory pathway.
Potent synthetic and endogenous ligands for the adopted orphan nuclear receptor Nurr1.
Jang Y, Kim W, Leblanc P, Kim CH, Kim KS
This review identifies specific endogenous and synthetic molecules that bind to and activate the Nurr1 protein, which is encoded by the NR4A2 gene. It outlines how these ligands stabilize the protein's structure and suggests they may offer therapeutic potential for neurodegenerative or inflammatory conditions.
- Nurr1 has a dynamic binding pocket that allows small molecules to activate it.
- Prostaglandins and other endogenous compounds act as natural Nurr1 ligands.
- Synthetic agonists are developed to potentially treat neurodegenerative diseases.
- The paper reviews mechanisms without testing treatments in humans or NR4A2 patients.
Activation of MC1R with BMS-470539 attenuates neuroinflammation via cAMP/PKA/Nurr1 pathway after neonatal hypoxic-ischemic brain injury in rats.
Yu S, Doycheva DM, Gamdzyk M, Yang Y, Lenahan C, Li G, Li D, Lian L, Tang J, Lu J, Zhang JH
Activating the MC1R receptor with a specific drug reduces brain inflammation and improves neurological outcomes in rats after oxygen deprivation injury. This protective effect relies on the cAMP/PKA/Nurr1 signaling pathway, as blocking Nurr1 eliminates the benefit.
- MC1R activation reduces brain damage and inflammation in rat models of hypoxic-ischemic injury.
- The neuroprotective effect requires functional Nurr1, linking MC1R to NR4A2 pathways.
- CRISPR knockout of Nurr1 reverses the benefits of MC1R activation.
- This study uses neonatal rats, not humans or NR4A2 mutation models.
Lipoic acid alleviates LPS‑evoked PC12 cell damage by targeting p53 and inactivating the NF‑κB pathway.
Mao J, Gao H, Bai W, Zeng H, Ren Y, Liu Y, Yang X
Lipoic acid reduces inflammation and cell death in a Parkinson's disease cell model by blocking specific stress pathways. This study uses rat nerve cells to show that lipoic acid can protect against inflammatory damage, but it does not test this treatment in humans or children with NR4A2 syndrome.
- The study uses rat PC12 cells, not human patients or NR4A2-specific models.
- Lipoic acid reduced inflammatory markers and cell death in the lab setting.
- No clinical data exists for lipoic acid treatment in humans with this syndrome.
- Findings are preclinical and do not translate to immediate therapeutic options.
Expression Profiling of Rectal Biopsies Suggests Altered Enteric Neuropathological Traits in Parkinson's Disease Patients.
Cossais F, Schaeffer E, Heinzel S, Zimmermann J, Niesler B, Röth R, Rappold G, Scharf A, Zorenkov D, Lange C, Barrenschee M, Margraf NG, Ellrichmann M, Berg D, Böttner M, Wedel T
Researchers find that rectal tissue from Parkinson's disease patients shows altered gene expression related to nerve and mitochondrial function compared to healthy controls. This suggests that intestinal neuropathological changes are common in Parkinson's but does not provide information specific to NR4A2-related syndromes or potential treatments for them.
- Study analyzes rectal biopsies from Parkinson's patients and healthy controls.
- Altered gene expression found in 9 out of 12 Parkinson's patients.
- Changes involve neuroglial, mitochondrial, and inflammatory pathways.
- Findings confirm intestinal neuropathology is common in Parkinson's disease.
- No data on NR4A2 variants or specific therapies for this syndrome.
Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson's Disease.
Contaldi E, Magistrelli L, Milner AV, Cosentino M, Marino F, Comi C
This study measures NR4A2 levels in immune cells of Parkinson's patients to see if they predict motor complications, but it does not test treatments or address the neurodevelopmental aspects of NR4A2 syndrome. The findings are specific to adult-onset Parkinson's disease and do not translate to clinical management for children with NR4A2-related disorders.
- NR4A2 levels in T cells differ between Parkinson's patients with and without motor complications.
- The study focuses on immune system changes, not brain development or motor function in children.
- Results do not inform treatment strategies for NR4A2 syndrome.
- This is observational research in adults, not a clinical trial or pediatric study.
Research on developing drugs for Parkinson's disease.
Zhang CL, Han QW, Chen NH, Yuan YH
This review outlines various molecular targets and drug development strategies for Parkinson's disease, including Nurr1 (NR4A2), but does not present new clinical data or specific treatments for NR4A2-related syndromes. It highlights that current dopaminergic therapies remain symptomatic while exploring novel mechanisms like immunotherapy and glutamate receptor modulation.
- Nurr1 is identified as one of several emerging molecular targets for Parkinson's drug development.
- Current treatments are limited to symptomatic relief with significant side effects.
- The review covers both preclinical studies and clinical improvements in dopaminergic drugs.
- Immunotherapy and shared pathological mechanisms with Alzheimer's and diabetes are also discussed.
Adolescent oxycodone exposure inhibits withdrawal-induced expression of genes associated with the dopamine transmission.
Carpenter MD, Manners MT, Heller EA, Blendy JA
Adolescent exposure to oxycodone causes lasting changes in brain gene activity related to dopamine, which may increase vulnerability to addiction later in life. These changes are driven by epigenetic mechanisms that silence dopamine-related genes long after drug use stops.
- Oxycodone in adolescence alters dopamine gene expression long-term
- Epigenetic marks suppress brain genes involved in reward
- Changes persist into adulthood, unlike in adult exposure
- This may increase addiction risk due to disrupted brain development
NURR1 Alterations in Perinatal Stress: A First Step towards Late-Onset Diseases? A Narrative Review.
Bordoni L, Petracci I, Calleja-Agius J, Lalor JG, Gabbianelli R
This narrative review discusses how perinatal stress and environmental factors can alter NURR1 expression, potentially linking early-life events to late-onset diseases. It proposes NURR1 as a prognostic marker or therapeutic target but does not present new clinical data or treatment results for NR4A2-related syndromes.
- NURR1 mediates responses to perinatal stress and influences dopaminergic neuron development.
- Maternal inflammation and neurotoxins alter NURR1 expression in gestational tissues.
- The paper reviews potential links between early NURR1 changes and adult diseases.
- No clinical trials or human patient outcomes for NR4A2 variants are reported.
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
Munoz-Tello P, Lin H, Khan P, de Vera IMS, Kamenecka TM, Kojetin DJ
This study identifies which previously reported drugs actually bind directly to the NR4A2 protein and reveals that many do not. It also shows that these compounds affect gene activity through mechanisms unrelated to NR4A2, complicating their use as targeted therapies.
- Only amodiaquine, chloroquine, and cytosporone B bind directly to the NR4A2 protein.
- Nine other tested ligands do not bind NR4A2 despite affecting gene transcription.
- Many ligands influence transcription independently of NR4A2 in a cell-specific manner.
- Results clarify which compounds are valid starting points for drug development.
Identification of Pathways and Key Genes in Venous Remodeling After Arteriovenous Fistula by Bioinformatics Analysis.
Jie K, Feng W, Boxiang Z, Maofeng G, Jianbin Z, Zhaoxuan L, Yangyi Z, Liang C, Haobo S, Wensheng L, Guoping C, Jianping G, Xu H, Jianyan W
This study identifies NR4A2 as a gene that increases in human veins when they adapt to high blood flow from dialysis fistulas. The research focuses on vascular biology and does not address the neurological or developmental aspects of NR4A2-related syndromes.
- NR4A2 expression increases in human veins after arteriovenous fistula creation.
- The study analyzes venous remodeling mechanisms for dialysis access maturation.
- No findings relate to brain development, dopamine neurons, or NR4A2 syndrome phenotypes.
DNA methylation and psychotherapy response in trauma-exposed men with appetitive aggression.
Xulu KR, Womersley JS, Sommer J, Hinsberger M, Elbert T, Weierstall R, Kaminer D, Malan-Müller S, Seedat S, Hemmings SMJ
This study links changes in DNA methylation of the NR4A2 gene to reduced PTSD symptoms in adults undergoing psychotherapy for trauma-related aggression. It does not provide evidence on NR4A2 syndrome development, treatment efficacy for children, or genetic mechanisms specific to pediatric neurodevelopmental disorders.
- Study focuses on adult men with trauma and appetitive aggression, not children.
- NR4A2 methylation changes correlate with PTSD symptom reduction in psychotherapy patients.
- Research examines epigenetic responses to therapy, not NR4A2 syndrome pathology.
- Findings do not translate to pediatric neurodevelopmental outcomes or treatments.
Effect of selected bisphenol derivatives on nuclear receptor expression in ovarian cell line COV434.
Mlynarcikova AB, Scsukova S
This study shows that common plastic chemicals can alter the expression of NURR1 in human ovarian cells, but it provides no information on how this affects brain development or NR4A2-related syndromes. The findings are limited to cell culture experiments and do not translate to clinical outcomes for children with genetic variants.
- Bisphenol chemicals increased NURR1 mRNA levels in human ovarian cells at high concentrations.
- The study used a granulosa cell line, not brain or neural tissue relevant to NR4A2 syndromes.
- No changes occurred in other nuclear receptors or cell viability during the experiment.
- Results do not inform treatment, prognosis, or phenotype for NR4A2-related disorders.